-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insider Buying: Antibe Therapeutics Inc. (TSE:ATE) Senior Officer Acquires C$12,400.00 in Stock
Insider Buying: Antibe Therapeutics Inc. (TSE:ATE) Senior Officer Acquires C$12,400.00 in Stock
Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis bought 20,000 shares of the stock in a transaction on Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the purchase, the insider now directly owns 80,000 shares in the company, valued at approximately C$49,600.
ATE stock opened at C$0.60 on Thursday. The stock has a market capitalization of C$30.83 million and a P/E ratio of -1.12. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. Antibe Therapeutics Inc. has a one year low of C$0.59 and a one year high of C$3.65. The company has a 50 day moving average price of C$0.66 and a two-hundred day moving average price of C$0.70.
Get Antibe Therapeutics alerts:About Antibe Therapeutics (Get Rating)
Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.Recommended Stories
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis bought 20,000 shares of the stock in a transaction on Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the purchase, the insider now directly owns 80,000 shares in the company, valued at approximately C$49,600.
安提贝治疗公司(多伦多证券交易所代码：ATE-GET评级)高级官员斯科特·威尔逊·柯蒂斯在7月8日星期五的一笔交易中购买了2万股该股。该股是以每股0.62加元的平均成本购买的，总价值为12,400.00加元。收购完成后，这位内部人士现在直接拥有该公司8万股，价值约49,600加元。
ATE stock opened at C$0.60 on Thursday. The stock has a market capitalization of C$30.83 million and a P/E ratio of -1.12. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. Antibe Therapeutics Inc. has a one year low of C$0.59 and a one year high of C$3.65. The company has a 50 day moving average price of C$0.66 and a two-hundred day moving average price of C$0.70.
ATE股票周四开盘报0.60加元。该股市值为3,083万加元，市盈率为-1.12。该公司的负债权益比率为0.29，速动比率为11.92，流动比率为13.07。安提贝治疗公司的股价一年来最低为0.59加元，一年最高为3.65加元。该公司的50日移动均线价格为0.66加元，200日移动均线价格为0.70加元。
About Antibe Therapeutics (Get Rating)
关于安提贝治疗公司(获取评级)
Recommended Stories
推荐故事
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
- 下半年将再考虑3只股票
- 联合天然食品库存准备好被点心
- 弹性股票是一种活跃的搜索业务
- 3M(纽约证券交易所代码：MMM)评级下调后，现在是买入3M的好时机吗？
- 苹果全球智能手机市场份额增长20%，你应该考虑股票吗？
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《安提贝治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对安替比治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧